FYN was reported to be correlated with cell motility and proliferation and over-expressed in chronic myeloid leukemia, breast cancer, squamous head and neck carcinoma, and melanoma [38]. Here, FYN is linked to chronic myelogenous leukemia, BCR-ABL1 positive.